FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012886521> ?p ?o ?g. }

• W2012886521 endingPage "35" @default.
• W2012886521 startingPage "19" @default.
• W2012886521 abstract "Abstract The relationship between breast cancer‐associated fatty acid synthase (FAS; oncogenic antigen‐519) and chemotherapy‐induced cell damage has not been studied. We examined the ability of C75, a synthetic slow‐binding inhibitor of FAS activity, to modulate the cytotoxic activity of the microtubule‐interfering agent Taxol™ (paclitaxel) in SK‐Br3, MDA‐MB‐231, MCF‐7 and multidrug‐resistant MDR‐1 (P‐Glycoprotein)‐overexpressing MCF‐7/AdrR breast cancer cells. When the combination of C75 with Taxol™ in either concurrent (C75 + Taxol™ 24 hr) or sequential (C75 24 hr → Taxol™ 24 hr) schedules were tested for synergism, addition or antagonism using the isobologram and the median‐effect plot analyses, co‐exposure of C75 and Taxol™ mostly demonstrated synergistic effects, whereas sequential exposure to C75 followed by Taxol™ mainly showed additive or antagonistic interactions. Because the nature of the cytotoxic interactions was definitely schedule‐dependent in MCF‐7 cells, we next evaluated the effects of C75 on Taxol™‐induced apoptosis as well as Taxol™‐activated cell death and cell survival‐signaling pathways in this breast cancer cell model. An ELISA for histone‐associated DNA fragments demonstrated that C75 and Taxol™ co‐exposure caused a synergistic enhancement of apoptotic cell death, whereas C75 pre‐treatment did not enhance the apoptosis‐inducing activity of Taxol™. Co‐exposure to C75 and Taxol™ induced a remarkable nuclear accumulation of activated p38 mitogen‐activated protein kinase (p38 MAPK), which was accompanied by a synergistic nuclear accumulation of the p53 tumor‐suppressor protein that was phosphorylated at Ser46, a p38 MAPK‐regulated pro‐apoptotic modification of p53. As single agents, FAS blocker C75 and Taxol™ induced a significant stimulation of the proliferation and cell survival mitogen‐activated protein kinase extracellular signal‐regulated kinase (ERK1/ERK2 MAPK) activity, whereas, in combination, they interfered with ERK1/ERK2 activation. Moreover, the combined treatment of C75 and Taxol™ inactivated the anti‐apoptotic AKT (protein kinase B) kinase more than either agent alone, as evidenced by a synergistic down‐regulation of AKT phosphorylation at its activating site Ser 473 without affecting AKT protein levels. To rule out a role for non‐FAS C75‐mediated effects, we finally used the potent and highly sequence‐specific mechanism of RNA interference (RNAi) to block FAS‐dependent signaling. Importantly, SK‐Br3 and multi‐drug resistant MCF‐7/AdrR cells transiently transfected with sequence‐specific double‐stranded RNA oligonucleotides targeting FAS gene demonstrated hypersensitivity to Taxol™‐induced apoptotic cell death. Our findings establish for the first time that FAS blockade augments the cytotoxicity of anti‐mitotic drug Taxol™ against breast cancer cells and that this chemosensitizing effect is schedule‐dependent. We suggest that the alternate activation of both the pro‐apoptotic p38 MAPK‐p53 signaling and the cytoprotective MEK1/2 → ERK1/2 cascade, as well as the inactivation of the anti‐apoptotic AKT activity may explain, at least in part, the sequence‐dependent enhancement of Taxol™‐induced cytotoxicity and apoptosis that follows inhibition of FAS activity in breast cancer cells. If chemically stable FAS inhibitors demonstrate systemic anticancer effects of FAS inhibition in vivo , these findings may render FAS as a valuable molecular target to enhance the efficacy of taxanes‐based chemotherapy in human breast cancer. © 2004 Wiley‐Liss, Inc." @default.
• W2012886521 created "2016-06-24" @default.
• W2012886521 creator A5012328790 @default.
• W2012886521 creator A5047280933 @default.
• W2012886521 creator A5077187730 @default.
• W2012886521 creator A5083270986 @default.
• W2012886521 date "2005-01-18" @default.
• W2012886521 modified "2023-10-13" @default.
• W2012886521 title "Pharmacological and small interference RNA‐mediated inhibition of breast cancer‐associated fatty acid synthase (oncogenic antigen‐519) synergistically enhances Taxol (paclitaxel)‐induced cytotoxicity" @default.
• W2012886521 cites W1611419331 @default.
• W2012886521 cites W1867114068 @default.
• W2012886521 cites W1869386995 @default.
• W2012886521 cites W1919928987 @default.
• W2012886521 cites W1937607074 @default.
• W2012886521 cites W1973417968 @default.
• W2012886521 cites W1975644211 @default.
• W2012886521 cites W1985385381 @default.
• W2012886521 cites W1986261554 @default.
• W2012886521 cites W1995741673 @default.
• W2012886521 cites W1999001280 @default.
• W2012886521 cites W2012220368 @default.
• W2012886521 cites W2012939857 @default.
• W2012886521 cites W2017093906 @default.
• W2012886521 cites W2018380648 @default.
• W2012886521 cites W2026238154 @default.
• W2012886521 cites W2038798987 @default.
• W2012886521 cites W2039163595 @default.
• W2012886521 cites W2039731227 @default.
• W2012886521 cites W2042676891 @default.
• W2012886521 cites W2047186447 @default.
• W2012886521 cites W2048997359 @default.
• W2012886521 cites W2053485292 @default.
• W2012886521 cites W2058168165 @default.
• W2012886521 cites W2060932390 @default.
• W2012886521 cites W2065841267 @default.
• W2012886521 cites W2067299834 @default.
• W2012886521 cites W2070124229 @default.
• W2012886521 cites W2072019190 @default.
• W2012886521 cites W2077945404 @default.
• W2012886521 cites W2080125477 @default.
• W2012886521 cites W2081406767 @default.
• W2012886521 cites W2085328130 @default.
• W2012886521 cites W2087835005 @default.
• W2012886521 cites W2088308108 @default.
• W2012886521 cites W2090846942 @default.
• W2012886521 cites W2093168199 @default.
• W2012886521 cites W2093265805 @default.
• W2012886521 cites W2098100188 @default.
• W2012886521 cites W2100403180 @default.
• W2012886521 cites W2102185138 @default.
• W2012886521 cites W2113966497 @default.
• W2012886521 cites W2118733942 @default.
• W2012886521 cites W2124809046 @default.
• W2012886521 cites W2165039236 @default.
• W2012886521 cites W2166903671 @default.
• W2012886521 cites W2186847038 @default.
• W2012886521 cites W2314171421 @default.
• W2012886521 cites W2320141410 @default.
• W2012886521 cites W2418761701 @default.
• W2012886521 doi "https://doi.org/10.1002/ijc.20754" @default.
• W2012886521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15657900" @default.
• W2012886521 hasPublicationYear "2005" @default.
• W2012886521 type Work @default.
• W2012886521 sameAs 2012886521 @default.
• W2012886521 citedByCount "101" @default.
• W2012886521 countsByYear W20128865212012 @default.
• W2012886521 countsByYear W20128865212013 @default.
• W2012886521 countsByYear W20128865212014 @default.
• W2012886521 countsByYear W20128865212015 @default.
• W2012886521 countsByYear W20128865212016 @default.
• W2012886521 countsByYear W20128865212017 @default.
• W2012886521 countsByYear W20128865212018 @default.
• W2012886521 countsByYear W20128865212019 @default.
• W2012886521 countsByYear W20128865212020 @default.
• W2012886521 countsByYear W20128865212021 @default.
• W2012886521 countsByYear W20128865212022 @default.
• W2012886521 countsByYear W20128865212023 @default.
• W2012886521 crossrefType "journal-article" @default.
• W2012886521 hasAuthorship W2012886521A5012328790 @default.
• W2012886521 hasAuthorship W2012886521A5047280933 @default.
• W2012886521 hasAuthorship W2012886521A5077187730 @default.
• W2012886521 hasAuthorship W2012886521A5083270986 @default.
• W2012886521 hasBestOaLocation W20128865211 @default.
• W2012886521 hasConcept C109316439 @default.
• W2012886521 hasConcept C121608353 @default.
• W2012886521 hasConcept C154317977 @default.
• W2012886521 hasConcept C184235292 @default.
• W2012886521 hasConcept C185592680 @default.
• W2012886521 hasConcept C190283241 @default.
• W2012886521 hasConcept C202751555 @default.
• W2012886521 hasConcept C2777292972 @default.
• W2012886521 hasConcept C31573885 @default.
• W2012886521 hasConcept C502942594 @default.
• W2012886521 hasConcept C51551487 @default.
• W2012886521 hasConcept C54355233 @default.
• W2012886521 hasConcept C55493867 @default.
• W2012886521 hasConcept C57074206 @default.
• W2012886521 hasConcept C86803240 @default.

• next